Patents by Inventor Andrew W. Patterson

Andrew W. Patterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11787785
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 17, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Y F Ting
  • Publication number: 20230108325
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: March 14, 2022
    Publication date: April 6, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela YF TING
  • Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • Publication number: 20220402904
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: December 16, 2020
    Publication date: December 22, 2022
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela TING
  • Publication number: 20220202787
    Abstract: Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 30, 2022
    Inventors: Simone Bonazzi, Michael Connolly, David Jonathan Glass, Andrew W. Patterson, Tea Shavlakadze
  • Publication number: 20220064185
    Abstract: The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 3, 2022
    Inventors: Simone Bonazzi, Michael Connolly, David Jonathan Glass, Manuel Mihalic, Andrew W. Patterson, Silvio Roggo, Tea Shavlakadze, Patrik Zueger
  • Patent number: 9085536
    Abstract: Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the aconitine derivatives.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: July 21, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Justin Du Bois, Brian M. Andresen, Frederic Menard, Andrew W. Patterson
  • Patent number: 8476451
    Abstract: The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The compounds of the invention are highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: July 2, 2013
    Assignee: The Regents of the University of California
    Inventors: Jonathan A. Ellman, Andrew W. Patterson, Hillary Peltier
  • Publication number: 20110263650
    Abstract: The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The essential features for the potent cytotoxicity of tubulysin D have been established for the first time by the synthesis and evaluation of a series of analogues. By identifying functionality that surprisingly is not necessary for activity, highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.
    Type: Application
    Filed: July 21, 2008
    Publication date: October 27, 2011
    Applicant: HELMHOLTZ-ZENTRUM FÜR INFEKTIONS-FORSCHUNG GMBH
    Inventors: Jonathan A. Ellman, Andrew W. Patterson, Hillary Peltier, Florenz Sasse
  • Publication number: 20110021568
    Abstract: The present invention provides novel tubulysin analogues, methods of making and methods of using such analogues and conjugates thereof. The compounds of the invention are highly potent cell-growth inhibitors have been developed that are smaller and considerably more stable than tubulysin D.
    Type: Application
    Filed: July 21, 2008
    Publication date: January 27, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jonathan A. Ellman, Andrew W. Patterson, Hillary Peltier
  • Patent number: 6932314
    Abstract: Sleeves for use in systems for supporting platform-like objects on casters and posts and described. The sleeves support caster-and-post junctions and inhibit deformation of the stems of the casters and the ends of posts in directions radially outward from the longitudinal axes of the stems and posts.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: August 23, 2005
    Assignee: Beijing Trade Exchange, Inc.
    Inventors: Andrew W. Patterson, Steven Snyder, Magdalena Kotek